Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

In radioligand therapies, Novartis is waiting to hear back from the FDA on its application for PSMA-targeted Pluvicto in pre-taxane metastatic castration-resistant prostate cancer. After an early ...

According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...